UNITED THERAPEUTICS Corp
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
(c)Trading Plans
On November 6, 2024, James Edgemond, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 111,500 stock options and sell the shares of common stock received, subject to certain conditions.
On December 24, 2024, Paul Mahon, a Section 16 officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 220,000 stock options and sell the shares of common stock received, subject to certain conditions.
| 67 | United Therapeutics, a public benefit corporation |
On December 24, 2024, Christopher Causey, amember of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) to exercise up to 3,000 stock options and sell the shares of common stock received, subject to certain conditions.
During the fourth quarter of December 31, 2024, no director or Section 16 officer terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408 of Regulation S-K).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.